Persistent pulmonary hypertension of the newborn (PPHN) is a devastating illness characterized by pulmonary hypertension, right to left shunting of blood via the foramen ovale and the ductus arteriosus and a structurally normal heart. In the National Institute of Child Health and Human Development (NICHD) Neonatal Observational Study of PPHN, the incidence (measured among infants delivered in high risk centers only) was 1.9/1,000 live births. A diverse number of processes including hypoxemia may lead to the dinical picture recognized as PPHN (1) . Fetal hypoxemia has been shown to occur with maternal tobacco smoke exposure (2, 3) . We hypothesize that maternal tobacco smoke exposure is a risk factor for PPHN in her newborn. Cotinine, a metabolite of nicotine, is a useful biological marker for nicotine exposure and is in widespread use to validate self-reported smoking status (4) . Cotinine has a half life of 15-40 hr in adults and 37-160 hr in infants (5) . Cotinine levels have been used as a measure of passive smoking (6, 7) . Cotinine levels in maternal serum during the second trimester of pregnancy are more predictive of birthweight than smoking history (g).
We undertook a study to investigate the association between maternal and fetal nicotine exposure and PPHN, using cotinine as a biomarker of exposure.
Methods
Subject. The Statistical analysis. Graphical and univariate statistics were used initially to describe the data and determine the appropriateness of parametric or nonparametric tests of significance. Nominal variables were described as frequencies, ordinal or nonparametric interval variables are described by medians and ranges, and interval, parametric data are described by means and standard deviations (SD). The sample characteristics of the mothers and the infants were examined to determine if any unanticipated differences between the groups existed. Nominal variables were tested using chisquared analysis or Fisher's exact test as appropriate; two sample t-tests were used for normally distributed data, and MannWhitney (or two sample Wilcoxon rank sum) tests were used for skewed data. Any variable with a p-value <0.2 was considered for entry into a multivariate model to control for residual confounding.
The association between cotinine levels and disease status was examined in two phases. Cotinine Table 4 . Due to the small number of study participants with exposure, dose and timing of exposure were not analyzed. Table 4 represents the number of women who were exposed at least once during the pregnancy to the chemicals listed and their T-ACE scores. No significant differences were observed, with the exception of antinausea preparations.
The cotinine concentrations of the newborn's blood were compared to maternal self-reported smoking status (Fig. 1) . Two women who reported no smoking had cord blood cotinine concentrations consistent with active smoking. To determine if our results agreed with external studies, we used the previously published interval values defining cotinine concentration by smoking status: no exposure <1 ng/ml; passive smoke exposure, 1-13.7 ng/ml; and active smoker >13.7 ng/ml (14) . We looked at our data by reported smoking status to determine if the cotinine values Table  5 . There was a significant association between our data and literature-based data (chi-square p = 0.025). Cotinine concentrations were compared between the infants with PPHN and the comparison group (Fig. 2) . Cotinine was detectable in the blood of 64.5% (20/31) study infants and 28.2% (11/39) comparison infants (p = 0.002). The distribution of detectable cotinine concentrations, shown in Figure 2 , is clearly higher in the PPHN group than in the comparison group (medians are 5.2 ng/ml for PPHN and 2.0 ng/ml for comparison; Mann-Whitney one-sided p-value = 0.05 1).
To assess the impact of passive smoke exposure, we reanalyzed the data for both groups excluding active smokers as defined by self report and/or a cotinine concentration >13.7 mg/ml (14) . The results are shown in Figure 3 . Cotinine was detected in the blood of 50% (11/22) study infants as compared to 18% (6/32) comparison infants (p = 0.0 15) of apparently nonsmoking women. The distribution of detectable cotinine concentrations, shown in Figure  3 , is also significantly higher in the PPHN group (medians are 3.5 ng/ml for PPHN and 1.65 ng/ml for comparison; Mann- Figure 1 . Relationship between maternal selfreported smoking status and cotinine concentration of infant's blood. The black horizontal lines indicate cotinine concentrations of 1 ng/ml and 13.7 ng/ml, which correspond to no exposure (<1 ng/ml), passive (1-13.7 ng/ml), and active (>13.7 ng/ml) smoking. Abbreviations: PPHN, persistent pulmonary hypertension of the newborn; ND, not detectable. 
2). Discussion
Our results show that cotinine was more likely to be found in the blood of infants with PPHN than in that of comparison infants, and that the cotinine concentrations were significantly higher in the PPHN group than in the comparison group. In addition, to examine the role of passive smoking, active smokers were excluded from analysis. The prevalence of significant concentrations of cotinine was again higher in the PPHN group, suggesting an association between environmental tobacco smoke exposure and PPHN. There are several possible explanations for our findings. First, cotinine may accumulate in the fetal compartment of compromised fetuses, giving rise to higher cotinine concentrations in the newborns' blood. This is unlikely due to its low ionization constant, pKa1 of 4.8. At physiologic or low ionization constant, physiologic pH, it will be predominantly nonionized and thus be able to rapidly diffuse across the placental barrier as shown by Luck et al. (15) .
Second, there may be decreased metabolism of cotinine by the PPHN fetuses, but that should not result in higher cotinine concentrations. Because nicotine and cotinine both rapidly equilibrate between the maternal-fetal compartments (15) and the mixed function oxidases have little activity in fetal liver (16) , the majority of cotinine and nicotine must be metabolized by the maternal liver. Thus, the cotinine half-life in utero is not dependent on fetal liver metabolism.
Third, the time between the last exposure to tobacco smoke and the blood drawing was shorter for the PPHN group than for the comparison group. This explanation for our findings is unlikely for several reasons. Since we used the first blood obtained after transport of the baby to our hospital in 12 cases, the length of time between last exposure and blood drawing is already biased towards a longer interval for the PPHN infants. Also, the half-life of cotinine in children is 37-160 hr. The interval between last exposure and obtaining cord blood would have to differ between the groups by at least 24 hr to become significant. One that the mothers smoked less, which is consistent with our findings. The other explanation, that these mothers were hospitalized in labor for greater than 24 hr, is not consistent with our data. In our comparison group, no mother had prolonged or difficult labor. In addition, the majority of mothers in our study (50/70) did not report smoking or passive smoke exposure. Therefore, no interval could be obtained from them between their last exposure and time of birth.
Finally, PPHN infants could be exposed to more nicotine while in utero. The only biological source of nicotine is from exposure to tobacco and other nicotine-containing plants. While ingestion of nicotine-containing vegetables may theoretically raise plasma cotinine levels (17) , the amount of raw vegetables that would need to be consumed to result in detectable levels of cotinine would require an unusual diet. In addition, there is no reason to assume that the diets of the two groups in this study were different. Thus, the most likely explanation of our finding is that mothers of the infants with PPHN are exposed to more tobacco or tobacco products.
We measured cotinine concentrations in the infants' blood because self-report of smoking or tobacco smoke exposure is known to be unreliable. This is evident in Figure 1 in which cotinine levels exceeded 100 ng/ml in women who denied smoking. In the PPHN group, cord blood was unavailable for some infants. In these cases, cotinine was measured in the first available blood. None of these infants had exposure to nicotine or cotinine through breast milk or passive smoking prior to blood sampling. Therefore, collecting blood from these infants rather than obtaining cord blood should only decrease the concentration of cotinine in their blood.
The prevalence of self-reported active smoking by mothers of the PPHN (20, 21) .
In the only other published study investigating the etiology of PPHN, self-reported use of aspirin, nonsteroidal anti-inflammatory drugs (NSAID), illicit drugs, and tobacco products were associated with PPHN (22) ; only aspirin and NSAID use remained statistically significant in multivariate analysis.
However, this study did not attempt to ascertain passive smoke exposure, nor were biochemical markers of exposure used. In contrast, we obtained a detailed exposure history from each study participant. We found no statistical difference in exposure to aspirin and NSAID or to cocaine. However, the numbers of women exposed were small in both groups, with low power to distinguish small differences in exposure between the two groups. We did find antinausea prescription drug use solely in the PPHN group. The use of antinausea prescription drugs should be considered in future studies of the etiology of PPHN to more fully delineate their possible role.
We are confident that the infants included in the PPHN group represent a relatively homogenous group. With the difficulty in establishing the diagnosis of PPHN (23), we used strict criteria for inclusion into this study. Only patients with both a diagnosis of PPHN by the attending neonatologist and a right to left shunt demonstrable on echocardiogram were included for study. These patients represent critically ill newborns with large AaDO2 and OI, with nearly half receiving extracorporeal membrane oxygenation. Therefore, both active and passive maternal exposure to tobacco smoke is a risk factor for PPHN. We encourage pregnant women to cease smoking and to avoid exposure to second-hand tobacco smoke.
